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doi: 10.1016/
j.xkme.2019.06.006New technologies such as genomics present opportunities to deliver precision medicine, including in the
diagnosis of rare kidney disorders. Simultaneously, social media platforms such as Twitter can provide
rapid and wide-reaching information dissemination in health care and science. We present 2 cases in
which the reporting of a novel genetic cause for human kidney disease was communicated through
Twitter and then subsequently noted by treating clinicians, thereby resulting in rapid clinical diagnostic
translation. In 1 family, this involved the reporting of heterozygous variants in GREB1L relating to auto-
somal dominant unilateral or bilateral renal agenesis, and in the other family, this involved biallelic variants
in CLDN10 relating to autosomal recessive hypokalemic renal tubular phenotypes. The times from Twitter
notification to clinical diagnostic genetic report for these families were 111 and 200 days, respectively.
Although caution is required, these cases show that social media platforms can contribute to rapid and
accessible academic communication that may benefit clinicians, genomics-based researchers, and pa-
tients and families affected by rare kidney diseases.© 2019 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).INTRODUCTION individual disorders within a field such as genetic kidneyWhere previously study of human genes, including their
diagnostic interrogation, was relatively limited to their
singular and sequential sequencing and analysis, techno-
logical advances have heralded the field of genomics, in
which many or all genes are sequenced and analyzed
concurrently, which enables speed, efficiency, and new
understanding of gene-phenotype relationships.1 Geno-
mics and its clinical applications have begun to affect
health care, specifically with regard to the diagnosis of rare
and undiagnosed diseases,2 including in nephrology.3
Genomic discovery in nephrology continues to progress
at an increasing pace,4 resulting in challenges for trans-
lation into diagnosis and therapy,5 the iterative addressing
of which is generating tangible clinical impact.6,7 Patients
and families with rare kidney disorders have great potential
to clinically benefit, although many previous genomic ef-
forts have focused on genetic discovery rather than clinical
translation for many rare and ultrarare kidney disorders.
Simultaneously, platforms are emerging that may enable
unexpected innovation and increased opportunity for
patient-level benefits to be realized.
One such platform is Twitter, which is already having a
positive effect in several areas of nephrology.8,9 This
platform enables perusal of information shared rapidly and
widely between individuals, groups, and institutions that
are able to form networks with similar interests. The
development of such co-interested and aligned networks
maximizes benefit and productivity that might be derived
across clinical research,10 different stakeholders,11 journal
clubs,12 and health care broadly.13 Although there are
facilities with individual journals or interest groups to
enroll in for targeted and regular updates on topics of
interest, the large number of relevant journals andKidney Med Vol 1 | Iss 5 | September/October 2019disease may make this challenging. A single platform such
as Twitter can leverage the combined capacities of jour-
nals, interest groups, academic and clinical institutions,
and individuals to disseminate information of interest
within networks of common interest and thus may
minimize such challenges and maximize visibility of
relevant content while strengthening interdisciplinary
care. The local protocol for genomic evaluation of rare
phenotypes has been published previously14 and is
described in Item S1.
We present 2 cases that support our hypothesis that
social media can play an important role in increasing
dissemination of medical knowledge, global communica-
tion, and opportunities for serendipity to occur, particu-
larly within the fields of human genetics and rare disease.
Reflecting this, the Tweets referred to below were identi-
fied by the treating clinician and study lead at random
without use of a targeted search strategy, notification
method, or other platform.CASE REPORT
The first family (RG_0080) presented in 2013 after 3
pregnancies affected by bilateral renal agenesis in the
context of asymptomatic 3-generation unilateral renal
agenesis (Fig 1A). After diagnostic genetic testing for
known forms of congenital abnormalities of the kidney
and urinary tract returned negative, the family enrolled in
a research genomics study. Whole-exome sequencing of 5
affected family members across 3 generations revealed
candidate heterozygous variants in 19 genes; none had a
known relationship with kidney disease, development, or
physiology.315
Figure 1. Family pedigrees and genomic outcomes. (A) Family RG_0080, unilateral and bilateral renal agenesis, and (B) family
RG_0129, hypokalemic metabolic alkalosis. Abbreviation: dx, diagnosis.
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Case ReportAt 5:00 AMAEST on Saturday, September 9, 2017, a Twitter
post by a clinician-researcher of the recent report of hetero-
zygous GREB1L variants associated with unilateral renal agen-
esis/bilateral renal agenesis15 was seen.16 The reporting of
GREB1L was important because there are a limited number of
known genes with a consistent andmonogenic relationship to
this phenotype. By 5:30 AM, the heterozygous candidate
variant list for this unresolved family was reviewed and a
segregating candidate GREB1L variant was identified from
among the family’s existing 19 gene candidate list. In concert
with 2 subsequent reports of humans,17,18 including an un-
related affected family with the same variant as this family,
diagnostic confirmation and reporting in an accredited labo-
ratory was enabled and progressed, with a diagnostic result
returned on December 29, 2017.
The second family (RG_0129), with significant con-
sanguinity and a single proband with an established
phenotype of hypokalemic metabolic alkalosis and variable
normocalciuria without overt nephrocalcinosis approxi-
mating Bartter syndrome type 3 (Fig 1B), was referred in
2016. Diagnostic genetic testing for hypokalemic tubulo-
pathies was negative. The family was enrolled in research
genomics with whole-genome sequencing undertaken in 1
affected and 2 unaffected family members. A candidate
homozygous variant in CLDN10 was identified. A submis-
sion to GeneMatcher19 on April 4, 2017, returned a single
result related to a phenotype our patient did not have.
The existing literature relating CLDN10 variants to kid-
ney tubular physiology and dysfunction in preclinical
models20-22 resulted in embarking on variant-specific
functional genomic modeling in a mouse model. The
day after this mouse model was established, a report of a
similar human renal tubular phenotype associated with
biallelic CLDN10 variants occured23 and was noted in a
Twitter post by the publishing journal at 7:00 AM AEST on
Tuesday, July 4, 2017.24 The reporting of CLDN10 was
significant because there were an already well-established
number of genes that have a monogenic relationship to
such hypokalemic metabolically alkalotic kidney pheno-
types. In company with other reports of humans of similar
though heterogeneous phenotypes,25,26 diagnostic
confirmation and reporting in an accredited laboratory was
undertaken, enabling the return of a clinically meaningful
result on January 19, 2018.DISCUSSION
In both families, reporting of new genetic causes for rare
kidney disease played a significant and synergistic role
with research genomics, clinical genomics, and patient
care. The times from Twitter notification of the first online
report to a clinical diagnostic genetic report for these
families were 111 and 200 days, respectively. It is
important to acknowledge the limitations of this infor-
mation dissemination medium, such as the authenticity of
individual Tweets and associated responses. Additionally,
although there are alternative social media platforms suchKidney Med Vol 1 | Iss 5 | September/October 2019as Facebook or blogs that may have similar functions, the
significant use of direct links to primary publications and
contributions from academic journals themselves, as
demonstrated in these 2 cases, potentially highlights the
strengths and validity of information disseminated through
Twitter.
Accordingly, we suggest appropriate critical review of
information disseminated in Tweets, including verification
of primary source information from journal websites,
conference proceedings, and the published literature. This
is important for all who might consume and propagate this
information, including patients and families, in addition to
clinicians and researchers who might all take part in social
media networks due to common interests and focus.
In the first family, it is difficult to predict whether a
clinical diagnostic report would have been possible in the
absence of the publication by Brophy et al15 (2017) and its
online sharing. For the second family, diagnostic trans-
lation was expedited and resource-intensive in-depth
functional genomic experimentation was avoided.
In the first instance, these 2 families demonstrate the
diagnostic power afforded by genomic sequencing tech-
nologies, particularly in ultrarare and diagnostically unre-
solved instances of likely heritable kidney disease. Second,
they highlight the meaningful acceleration of translation
from gene discovery to clinical practice and real-world
patient outcomes, including in sometimes novel, unex-
pected, and serendipitous ways. In both instances, missing
the otherwise random opportunity that was afforded to
access critical new academic information may have
significantly further delayed translation and diagnosis.
These instances also show how information disseminated
by different sources, such as other clinician-researchers
with similar interests and academic journals, demonstrate
the value of social medial amplification.
Although anecdotal, we suggest that these examples
demonstrate the promising and emerging role of Twitter as
a rapid and accessible academic information platform that
may benefit clinicians, genomics-based researchers, and
most importantly, patients and families affected by rare
and ultrarare kidney disease. Future initiatives incorpo-
rating machine learning and artificial intelligence ap-
proaches to amalgamate and monitor large amounts of
data are indicated to leverage such promise. Ongoing and
future progress will hinge upon global information ex-
change and collaboration across broadened multidisci-
plinary teams to deliver on the promise of genomics in
nephrology.SUPPLEMENTARY MATERIAL
Supplementary File (PDF)
Item S1: Protocol for genomic evaluation of rare phenotypes.
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